CHINA RESOURCES BOYA BIO-PHARMACEUTICAL GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.31 CNY | +2.15% |
|
-2.55% | -1.10% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.51 times its estimated earnings per share for the ongoing year.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -1.10% | 2.27B | - | ||
| -2.10% | 90.02B | A- | ||
| -0.66% | 39.15B | A- | ||
| -15.83% | 31.71B | B- | ||
| +62.42% | 26.47B | A | ||
| -21.68% | 14.34B | C | ||
| -8.73% | 12.89B | B- | ||
| -10.32% | 11.18B | D+ | ||
| -45.77% | 10.97B | B | ||
| +3.45% | 8.94B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 300294 Stock
- Ratings China Resources Boya Bio-pharmaceutical Group Co.,Ltd
